Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China

Huan Xia, Chengzhen Lu, Yin Wang, Silvère D. Zaongo, Yue Hu, Yue Wu, Zhongfang Yan, Ping MaFrontiers in Pharmacology 2020 · DOI

Abstract: In this large real-life single-center HCV cohort from China, oral DAAs were highly effective and well-tolerated. Further and larger-scale studies are needed to evaluate their clinical safety and efficacy.

Introduction

Direct-Acting Antivirals (DAAs) have revolutionized the treatment landscape for Chronic Hepatitis C (HCV), offering high cure rates and improved safety profiles compared to older interferon-based therapies. However, real-world data from mainland China remains limited, particularly regarding the performance of brand-name DAAs. Historically, the high cost of these medications restricted their use. In Tianjin, China, recent changes in health insurance policies—reimbursing 85–90% of treatment costs—have enabled broader access to brand-name DAAs. This study evaluates the efficacy and safety of these therapies in a real-world clinical setting.

Methods and Patient Cohort

This retrospective, single-center study was conducted at the Tianjin Second People’s Hospital, involving 494 adult patients treated between April 2018 and September 2019. The cohort included a diverse range of patient profiles, including those with cirrhosis and various HCV genotypes.

Hepatitis C virus (HCV) genotypes distribution among the 494 patients.

The primary endpoint was Sustained Virological Response at 12 weeks post-treatment (SVR12). Five DAA regimens were evaluated: Sofosbuvir + Ribavirin (SOF + RBV), Elbasvir/Grazoprevir (EBR/GZR), Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin (OBV/PTV/r/DSV ± RBV), Daclatasvir + Asunaprevir (DCV + ASV), and Sofosbuvir + Daclatasvir ± Ribavirin (SOF + DCV ± RBV).

Key Results

The overall SVR12 rate across the entire cohort was 96.96% (479/494). The study demonstrated that brand-name DAAs maintain high efficacy across different genotypes, treatment regimens, and patient subgroups.

SVR12 rates categorized by (A) HCV genotype, (B) DAA treatment regimen, and (C) patient clinical subgroups.

Specific findings include:

  • Regimen Efficacy: EBR/GZR achieved a 100% SVR12 rate, while DCV + ASV showed the lowest efficacy at 86.67%.
  • Subgroup Challenges: Patients with compensated cirrhosis (92.73%) and those who were treatment-experienced (77.78%) had lower SVR12 rates compared to treatment-naive patients (97.69%).
  • Genotype Sensitivity: GT3b (88.24%) and GT1a (0%, though n=1) were identified as more challenging to treat.
  • Safety: No serious adverse events (SAEs) were reported. Common mild adverse events included fatigue, anemia, and dizziness, affecting 38.5% of the population.

Discussion and Conclusion

The findings confirm that brand-name DAAs are highly effective and safe for treating HCV in a real-world Chinese population, mirroring results from international clinical trials. The study highlights the importance of supportive insurance policies in achieving these outcomes. However, challenges remain for specific "difficult-to-cure" groups, such as patients with cirrhosis or prior treatment failure. Future research should focus on larger multi-center studies and the role of resistance-associated substitutions (RAS) in optimizing treatment for these subgroups.

Summary updated

Abstract

In this large real-life single-center HCV cohort from China, oral DAAs were highly effective and well-tolerated. Further and larger-scale studies are needed to evaluate their clinical safety and efficacy.
BibTeX
@inproceedings{xia2020efficacy,
  author = {Huan Xia and Chengzhen Lu and Yin Wang and Silvère D. Zaongo and Yue Hu and Yue Wu and Zhongfang Yan and Ping Ma},
  title = {{Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China}},
  booktitle = {Frontiers in Pharmacology},
  year = {2020},
  doi = {10.3389/fphar.2020.00710},
}
Figure